[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6242 followers
Created: 2025-07-28 09:26:40 UTC

Tatva Chintan Pharma Chem Q1 FY26 Update: Revenue Up XX% YoY, Margins Improve 📈 | MCap XXXXXXXX Cr

- Q1 FY26 operating revenue: ₹1,169M (11% YoY ↑, X% QoQ ↑)
- EBITDA: ₹173M (37% YoY ↑, XX% QoQ ↑) with margins at XXXX%
- Exports contribute XX% revenue (₹830M) to key markets: Japan, USA, Germany
- Segment performance mixed: 
  • Phase Transfer Catalyst: -XX% QoQ but +9% YoY
  • Electrolyte Salts: +32% QoQ but -XX% YoY
  • Pharma & Agro Intermediates: +32% QoQ, +11% YoY
  • Structure Directing Agents: +14% QoQ, +13% YoY
- New agro intermediates production starts Q3
- Semiconductor chemicals commercialization expected 2027-2029
- FY26 Capex: ₹110Cr for new production blocks
- FY26 Guidance: XX% revenue growth, XX% EBITDA margins
- CFO Ashok Bothra announces departure
- Strategic R&D focus on semiconductor chemicals & energy storage

Complete Source:

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

Preview 👇 (First X out of XX pages)

![](https://pbs.twimg.com/media/Gw7zWrna4AApfIT.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1949763427171455018/c:line.svg)

**Related Topics**
[germany](/topic/germany)
[united states](/topic/united-states)
[japan](/topic/japan)
[mcap](/topic/mcap)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1949763427171455018)